High Ki‐67 expression in diffuse large B‐cell lymphoma patients with non‐germinal center subtype indicates limited survival benefit from R‐CHOP therapy
Authors:
- 13 March 2012
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 88 (6) , 510-517
Abstract
Objectives: Rituximab has significantly improved the survival of patients with DLBCL, especially those with non‐germinal center B‐cell‐like (non‐GCB) subtype. The impact of Ki‐67 expression, an index of proliferation, on the clinical outcomes of patients with DLBCL has largely been unexplored. This study aimed to investigate whether Ki‐67 expression is an indicator of outcome in DLBCL patients (especially non‐GCB DLBCL patients) treated with standard chemotherapy combined with rituximab.Methods: Expression of Ki‐67 protein was examined immunohistochemically in 118 tumor specimens from patients newly diagnosed with DLBCL and treated with R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).Results: Overall survival (OS) and progression‐free survival (PFS) were lower in patients with high Ki‐67 expression than in those with low Ki‐67 expression (3‐year OS: 65.2% vs. 81.7%, P = 0.030; 3‐year PFS: 56.4% vs. 73.3%, P = 0.020), similar in patients with GCB subtype and those with the non‐GCB subtype (OS: P = 0.330; PFS: P = 0.287). According to Ki‐67 expression status by immunophenotype subgroups, patients with high Ki‐67 expression in non‐GCB subgroup had the most unfavorable PFS and OS, comparing with the other three subgroups (P = 0.004 and P = 0.002, respectively). In multivariate analysis, non‐GCB with high Ki‐67 expression was an independent prognostic predictor of inferior survival in DLBCL patients treated with R‐CHOP.Conclusion: For DLBCL patients with non‐GCB DLBCL and high Ki‐67 expression, the survival benefit from R‐CHOP therapy is limited.Keywords
This publication has 27 references indexed in Scilit:
- Ki‐67 expression as a prognostic factor in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOPEuropean Journal of Haematology, 2010
- Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab eraCancer Science, 2009
- Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphomaLeukemia & Lymphoma, 2008
- Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapyBlood, 2007
- Prognostic Impact of Germinal Center–Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Proliferation Marker Ki-67 in Early Breast CancerJournal of Clinical Oncology, 2005
- Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosisLaboratory Investigation, 2005
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumorsMolecular Immunology, 2003
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993